The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.875
Bid: 2.75
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.25 (9.091%)
Open: 2.875
High: 3.00
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: easyJet And Foxtons In Post-Brexit Warnings

Mon, 27th Jun 2016 09:51

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.
----------
FTSE 100 - WINNERS
----------
Fresnillo, up 7.5% and Randgold Resources, up 7.0%. The gold miners were gaining again on the higher gold price, quoted at USD1,325.65 an ounce, compared to USD1,317.55 at the London equities close Friday. Goldman Sachs also upgraded Fresnillo to Neutral from Sell. Randgold was raised to Buy from Neutral by Goldman and to Buy from Hold by Panmure Gordon.

Diageo, up 3.5%. The distiller was upgraded to Hold from Sell by SocGen.
----------
FTSE 100 - LOSERS
----------
EasyJet, down 17%. The low cost carrier said pretax profit in its fiscal third quarter will be lower year-on-year following flight cancellations and the Egyptair tragedy and said the UK's vote to leave the European Union will hit revenue per seat in the second half of the year. The low-cost airline said it has experienced 1,061 cancellations so far in the third quarter to the end of June, due to a significant number of disruptive events including air traffic control strikes in France, runway and congestion issues at Gatwick airport and severe weather conditions. Those incidents hit third-quarter pretax profit by around GBP28 million year-on-year, easyJet said, while also reducing revenue per seat by around 1.6 percentage points. In addition, the Brexit decision will contribute to further economic and consumer uncertainty this summer, easyJet said, leading to an expected mid-single digit fall in revenue per seat at constant currency in the second half of the financial year, year-on-year.

Taylor Wimpey, down 12%, Barratt Developments, down 11%, Persimmon, 10%, Berkeley Group Holdings, down 9.4%. The housebuilders were continuing losses from Friday after the Brexit vote. The FTSE 350 Household Goods & Home Construction Index, which includes the largest London-listed housebuilders, was down 2.2%, having closed down 10% on Friday. Michael van Dulken, head of research at Accendo Markets said: "Weekend political upheaval from both sides and a leadership vacuum has done little to calm investor nerves about the near-term future, with the most sensitive stocks to the Leave vote - banks, property, airlines - getting another drubbing which has in some cases wiped out the recoveries seen on Friday from knee-jerk Brexit lows."

Travis Perkins, down 11%. The builder's merchant was cut to Underperform from Buy by Merrill Lynch, according to traders.

Royal Bank of Scotland Group, down 13%. The bank was cut to Neutral from Outperform by Exane BNP, to Sell from Hold by SocGen, and to Underweight from Equal Weight by Barclays.

Barclays, down 9.6%. The bank was downgraded to Neutral from Outperform by Exane BNP, to Underperform from Buy by Jefferies, and to Neutral from Overweight by JPMorgan.

International Consolidated Airlines Group, down 8.8%. The British Airways, Aer Lingus and Iberia parent company was downgraded to Neutral from Buy by Goldman Sachs following its profit warning on Friday.
----------
FTSE 250 - WINNERS
----------
UBM, up 10%. The media and events group said its share consolidation plan is effective from Monday following the sale of its PR Newswire business earlier this month. UBM had announced the sale of the business in late 2015 to Cision, a PR software company owned by Chicago-based private equity house GTCR Canyon Holdings, for total cash proceeds of GBP490.0 million. UBM has returned GBP245.0 million of the proceeds to shareholders via a special dividend, and its associated share consolidation of eight shares for nine is effective from Monday with the new shares issued for trading.

Acacia Mining, up 10%, Centamin, up 6.5%. The mid-cap gold miners miners were raised to Buy from Hold by Panmure and also were benefiting from the higher gold price.

Drax Group, up 3.5%. The biomass power plant operator was upgraded to Hold from Sell by Deutsche Bank.
----------
FTSE 250 - LOSERS
----------
Foxtons Group, down 24%. The London-focused estate agent said the UK's decision to leave the EU will add to the already-uncertain conditions in the London residential property market. Foxtons said it is too early to accurately predict what impact Brexit will have on London property sales, but it said the upturn it had been anticipating in the second half is now unlikely to materialise. As a result, revenue and adjusted earnings before interest, taxation, depreciation and amortisation will be "significantly lower" year-on-year in 2016, as challenging conditions continue through the remainder of the year.

Virgin Money Holdings, down 19%, Shawbrook Group, down 17%, OneSavings Bank, down 16%. The mid-cap financial stocks also continued to suffer from the Leave vote. The FTSE 350 banking index was down 5.4%, having closed down 9.8% on Friday.

Morgan Advanced Materials, down 15%. The ceramic materials manufacturer was cut to Neutral from Buy by Citigroup.

Balfour Beatty, down 11%. the construction and infrastructure group was downgraded to Neutral from Buy by Citi.
----------
MAIN MARKET AND AIM - WINNERS
----------
Surgical Innovations Group, up 10%. The surgical equipment maker said revenue in the first half of 2016 is expected to be 10% higher than the previous year, adding its new product ranges are still expected to be launched later this year. Speaking ahead of the company's annual general meeting later Monday in Leeds, Executive Chairman Nigel Rogers said the rise in revenue has been driven by strong demand from customers based in the US and should lead to an improved gross margin - which should exceed 25% of revenue. Surgical is expecting its inventory to have reduced by at least GBP500,000 during the first half, in line with management expectations, and the company is expecting to deliver further strong cash flows and "significantly reduced net debt" by the end of 2016.
----------
MAIN MARKET AND AIM - LOSERS
----------
Biome Technologies, down 31%. The bioplastics and radio frequency technology business said that, although its financial performance is expected to improve during 2016, its results will fail to meet board expectations after revenue came in lower than expected during the first half of the year. The group said revenue in the first half came in at GBP2.2 million, only a touch higher than the GBP2.1 million generated in 2015 and below the company's target for the period. This shortfall is due to a reduced demand for already commercialised products in the Bioplastics Division and some slippage of the Stanelco RF's division's order pipeline into the second half, Biome Technologies said.

Allergy Therapeutics, down 14%. The allergy vaccine specialist said the results of its Phase II dose-ranging study for the US GrassMATAMPL clinical development programme did not determine a recommended dose for the Phase III trial. GrassMATAMPL is an ultra-short-course subcutaneous allergen-specific immunotherapy, administered prior to the grass pollen season. The company said a further dose range finding study will be implemented prior to proceeding into the planned pivotal Phase III study. The next dose-range finding study is planned to start in 2017, and Allergy Therapeutics will await the outcome of an End of Phase II meeting with the US Food & Drug Administration later in 2016 before progressing into Phase III.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
27 Mar 2024 16:13

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
27 Mar 2024 11:02

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
12 Mar 2024 14:06

Allergy Therapeutics starts dosing patients in peanut allergy trial

(Alliance News) - Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.

Read more
1 Mar 2024 15:49

UK shareholder meetings calendar - next 7 days

Monday 4 March 
Ascent Resources PLCGM re bonus issue of preference shares
JPMorgan Emerging Europe, Middle East & Africa Securities PLCAGM
Lexington Gold LtdAGM
Tuesday 5 March 
Ajax Resources PLCGM re extension of investment mandate
Beowulf Mining PLCGM re capital raise
CC Japan Income & Growth Trust PLCAGM
Driver Group PLCAGM
Edinburgh Worldwide Investment Trust PLCAGM
Jersey Electricity PLCAGM
Wednesday 6 March 
Ecofin Global Utilities & Infrastructure Trust PLCAGM
Mila Resources PLCAGM
Paragon Banking Group PLCAGM
Thursday 7 March 
Asia Strategic Holdings LtdAGM
CT UK Capital & Income Investment Trust PLCAGM
Henderson Opportunities Trust PLCAGM
XPS Pensions Group PLCGM re directors' remuneration policy 2024
Friday 8 March 
Allergy Therapeutics PLCAGM
All Things Considered Group PLCAGM
Chenavari Toro Income Fund LtdAGM
Neo Energy Metals PLCAGM
Schroder UK Mid Cap Fund PLCAGM
Silverwood Brands PLCGM re proposed share capital reduction
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
14 Feb 2024 10:22

Allergy Therapeutics forecasts revenue drop but trials going well

(Alliance News) - Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further funding soon.

Read more
5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
30 Jan 2024 10:38

Allergy Therapeutics resumes trading on AIM; annual revenue plunges

(Alliance News) - Allergy Therapeutics PLC on Tuesday resumed trading on AIM after the release of its annual results.

Read more
27 Dec 2023 14:17

IN BRIEF: Allergy Therapeutics amends facility, plans warrant issue

Allergy Therapeutics PLC - Sussex-based biotechnology company specialising in allergy vaccines - Shares rise as firm enters amendment to the facility agreement it reached in early April with SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Deal provides Allergy Therapeutics with a GBP40 million secured loan facility of which GBP32.5 million is uncommitted. Facility is available to drawdown between January 15 and the same day in 2026, with interest payable semi-annually at 12% per year and a January 15, 2027 repayment date.

Read more
15 Dec 2023 21:09

EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
13 Dec 2023 10:11

Allergy Therapeutics shares jump as hails grass allergy jab data

(Alliance News) - Allergy Therapeutics PLC on Wednesday said that phase-3 trials of its grass allergy injection yielded positive results, moving the product closer to market entry.

Read more
13 Dec 2023 09:55

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
14 Nov 2023 11:56

Allergy Therapeutics says allergy therapy trial meets primary endpoint

(Alliance News) - Allergy Therapeutics PLC on Tuesday said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary endpoint.

Read more
14 Nov 2023 10:59

AIM WINNERS & LOSERS: Renalytix revenue halves; DP Poland trades well

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
6 Nov 2023 12:33

IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.